The immune energy of peptides overcomes herpes

The immune energy of Arecur peptides overcomes herpes

Most often, people encounter diseases that are caused by 1 and 2 types of herpes viruses: herpes on the lips and face and herpetic lesions of the genitals. If herpes occurs on the lips, in the mouths of the nasal passages or in the eye area, it causes significant discomfort, and if the rash affects the genitals, sexuality decreases, problems in the intimate sphere arise. [1-3] 

Herpes is transmitted mainly when the carrier’s body fluids (blood, saliva, semen, mucous secretions) come into contact with the sensitive areas of the body of a non-infected person.After that, the virus spreads inside the body, infects the nervous system, in particular nerve nodes, which practically ensures its lifelong existence in the host's body. This circumstance largely determines the chronic course of the infection, affects the nature of the treatment and its results.

Currently developed and approved clinical protocols are aimed at reducing the frequency of herpes recurrences and reducing the intensity of symptoms. However, despite the availability of antiviral therapy, the virus, which has settled inside the nerve nodes, as if in the fortified points of the fortress, stubbornly resists and continues to cause exacerbations. [4,5]

In the course of research conducted by scientists from Japan, South Korea, Great Britain, the USA, as well as Ukraine, it was established that immune peptides of natural origin have the most ancient tasks formed by evolution: to activate immune cells and direct lymphocytes to destroy pathogenic viruses. The activity of natural peptides contributes to the formation of a complex set of sequential and cross biological reactions that serve one purpose - to maintain the immune system in a  combat readiness state. The understanding of these mechanisms reasonably led to the introduction of drugs based on immune peptides into medical practice [6].

The immune energy of the Arecur®, which contains immune peptides, reliably protects our body from pathogenic bacteria and viruses [7-10]. If you use Arecur® in the form of capsules, effective natural peptides reach the intestine in an unchanged form, where the capsule dissolves. Then, entering the lymphatic system, they interact with immune cells and stimulate the production of immune defense proteins: immunoglobulins, cathelicidin, etc. [11-14]. In this way, the immune system additionally receives reliable tools to fight infection. It is important to effectively act on herpetic foci hidden in the nerve nodes, that is, to overcome the resistance of the "nerve fortifications" of the virus and destroy the danger with effective attacks of one's own immune cells directed by Arecur®. It is recommended to use Arecur® for anti-relapse purposes:1 capsule 2 times a day for 30 days. The anti-relapse course should be started at least 10 days after the disappearance of the manifestations of the last herpes relapse.

With genital herpes, Arecur® is used in the form of a suppository within 20 days from the moment of occurence of herpes rashes. For a more harmonious healing of erosions on the skin, it is advisable to use Arecur® Derma ointment 3-4 times a day. After the end of the first course of candles, in 10 days, it is necessary to start the second course for the purpose of anti-relapse. If the manifestations of herpes occur more than 3 times a year and they are accompanied by significant discomfort, pain and heal slowly, specialists recommend taking a course of anti-relapse immuno-correction using the Arecur® injections: 1 fl. 2 times a day for 20 days. Positive results of clinical observations of Arecur® use for the treatment of infections caused by viruses were published in 2020, in the International Journal of Immunology, New York, USA.[15]


1.    Crimi S, Fiorillo L, Bianchi A, et al. Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data. Viruses. 2019;11(5):463.
2.    Schneider SM, Pritchard SM, Wudiri GA, Trammell CE, Nicola AV. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor. mBio. 2019;10(3):e00732-19.
3.    Xu X, Zhang Y, Li Q. Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development. Rev Med Virol. 2019;29(4):e2054.
4.    Forbes H, Warne B, Doelken L, et al. Risk factors for herpes simplex virus type-1 infection and reactivation: Cross-sectional studies among EPIC-Norfolk participants. PLoS One. 2019;14(5):e0215553.
5.    Holub M, Stráníková A, Chalupa P, Arientová S, Roubalová K, Beran O. Frequent Recurrences of Genital Herpes Are Associated with Enhanced Systemic HSV-Specific T Cell Response. Can J Infect Dis Med Microbiol. 2020;2020:5640960.
6.    Fruitwala S, El-Naccache DW, Chang TL. Multifaceted immune functions of human defensins and underlying mechanisms. Semin Cell Dev Biol. 2019 Apr; 88: 163-172.
7.    Park MS, Kim JI, Lee I, Park S, Bae JY, Park MS. Towards the Application of Human Defensins as Antivirals. Biomol Ther (Seoul). 2018;26(3):242–254.
8.    Sankaran-Walters Sumathi, Hart Ronald, Dills Chantelle. Guardians of the Gut: Enteric Defensins. Frontiers in Microbiology. Vol. 8, 2017: 647 
9.    Ahmed A. Siman-Tov G., Hall G., Bhalla N., Narayanan A. Human Antimicrobial Peptides as Therapeutics for Viral Infections. Viruses 2019, 11, 704.
10.    Li W., Ma, G-X, Zhou, X-Xi. Apidaecin-type peptides: Biodiversity, structure-function relationships and mode of action. Peptides. 2006, 27(9):2350-9.
11.    Hara S, Sasaki T, Satoh-Takayama N, et al. Dietary Antigens Induce Germinal Center Responses in Peyer's Patches and Antigen-Specific IgA Production. Front Immunol. 2019;10:2432.
12.    Dillon A, Lo DD. M Cells: Intelligent Engineering of Mucosal Immune Surveillance. Front Immunol. 2019;10:1499.
13.    Komban RJ, Strömberg A, Biram A, et al. Activated Peyer's patch B cells sample antigen directly from M cells in the subepithelial dome. Nat Commun. 2019;10(1):2423.
14.    Chang JE, Buechler MB, Gressier E, Turley SJ, Carroll MC. Mechanosensing by Peyer's patch stroma regulates lymphocyte migration and mucosal antibody responses. Nat Immunol. 2019;20(11):1506–1516.
15.    Beniuk V, Goncharenko V, Kurchenko A, Tatskyy O, Konovalenko S, Vintoniuk S, Melnikov S, Nurimanov K, Podpriatov S. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. International Journal of Immunology. Vol. 8, No. 1, 2020, pp. 1-8.